Kura Oncology’s (KURA) Buy Rating Reaffirmed at TD Cowen

TD Cowen reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report released on Thursday morning,Benzinga reports.

KURA has been the subject of several other reports. HC Wainwright increased their price target on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group cut their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, November 19th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, UBS Group began coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $29.38.

Kura Oncology Trading Up 7.4 %

Shares of NASDAQ KURA opened at $10.80 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $9.06 and a twelve month high of $24.17. The company’s fifty day moving average is $17.88 and its 200-day moving average is $19.69. The stock has a market cap of $839.81 million, a price-to-earnings ratio of -4.58 and a beta of 0.86.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Suvretta Capital Management LLC boosted its position in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after buying an additional 870,000 shares during the last quarter. Armistice Capital LLC raised its position in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Finally, Artal Group S.A. lifted its stake in Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after acquiring an additional 151,828 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.